MX391117B - Inhibidores de magl. - Google Patents
Inhibidores de magl.Info
- Publication number
- MX391117B MX391117B MX2019005776A MX2019005776A MX391117B MX 391117 B MX391117 B MX 391117B MX 2019005776 A MX2019005776 A MX 2019005776A MX 2019005776 A MX2019005776 A MX 2019005776A MX 391117 B MX391117 B MX 391117B
- Authority
- MX
- Mexico
- Prior art keywords
- magl inhibitors
- compositions
- magl
- useful
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423099P | 2016-11-16 | 2016-11-16 | |
| PCT/US2017/061868 WO2018093947A1 (en) | 2016-11-16 | 2017-11-15 | Magl inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019005776A MX2019005776A (es) | 2019-12-05 |
| MX391117B true MX391117B (es) | 2025-03-21 |
Family
ID=62106678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019005776A MX391117B (es) | 2016-11-16 | 2017-11-15 | Inhibidores de magl. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10093635B2 (enExample) |
| EP (1) | EP3541821A4 (enExample) |
| JP (1) | JP7042547B2 (enExample) |
| KR (1) | KR20190077544A (enExample) |
| CN (1) | CN110267963B (enExample) |
| AR (1) | AR110089A1 (enExample) |
| AU (1) | AU2017361251B2 (enExample) |
| BR (1) | BR112019009994A2 (enExample) |
| CA (1) | CA3043615A1 (enExample) |
| CL (1) | CL2019001339A1 (enExample) |
| CO (1) | CO2019005059A2 (enExample) |
| CR (1) | CR20190241A (enExample) |
| DO (1) | DOP2019000122A (enExample) |
| EA (1) | EA038090B1 (enExample) |
| EC (1) | ECSP19035077A (enExample) |
| GE (2) | GEP20237470B (enExample) |
| IL (1) | IL266523B (enExample) |
| JO (1) | JOP20190106A1 (enExample) |
| MA (1) | MA46857A (enExample) |
| MX (1) | MX391117B (enExample) |
| NI (1) | NI201900051A (enExample) |
| PE (1) | PE20191144A1 (enExample) |
| PH (1) | PH12019501097A1 (enExample) |
| RU (1) | RU2754536C1 (enExample) |
| TN (1) | TN2019000153A1 (enExample) |
| TW (1) | TWI756299B (enExample) |
| UA (1) | UA124542C2 (enExample) |
| WO (1) | WO2018093947A1 (enExample) |
| ZA (1) | ZA201903100B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202000198T1 (it) | 2012-01-06 | 2020-07-08 | Scripps Research Inst | Composti di carbammato e metodi di produzione e di utilizzo degli stessi |
| MX2017014344A (es) | 2015-05-11 | 2018-04-11 | Abide Therapeutics Inc | Metodos para el tratamiento de la inflacion o el dolor neuropatico. |
| US10899737B2 (en) | 2016-09-19 | 2021-01-26 | Lundbeck La Jolla Research Center, Inc. | Piperazine carbamates and methods of making and using same |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| EP3541807B1 (en) | 2016-11-16 | 2021-09-29 | H. Lundbeck A/S | A crystalline form of a magl inhibitor |
| CN110290791A (zh) | 2016-11-16 | 2019-09-27 | 灵北拉荷亚研究中心公司 | 药物制剂 |
| RS64006B1 (sr) | 2017-05-23 | 2023-03-31 | H Lundbeck As | Pirazol magl inhibitori |
| MA50041A (fr) | 2017-08-29 | 2020-07-08 | Lundbeck La Jolla Research Center Inc | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci |
| SG11202011228TA (en) * | 2018-05-15 | 2020-12-30 | Lundbeck La Jolla Research Center Inc | Magl inhibitors |
| MA54827A (fr) * | 2019-01-25 | 2022-05-04 | H Lundbeck As | Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl |
| AU2020383502A1 (en) * | 2019-11-15 | 2022-06-30 | H. Lundbeck A/S | Crystalline forms of a MAGL inhibitor |
| IT202000007150A1 (it) * | 2020-04-03 | 2021-10-03 | Univ Pisa | Inibitori di monoacilglicerolo lipasi (magl) |
| WO2021214550A1 (en) | 2020-04-21 | 2021-10-28 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
| WO2023130023A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| US12378219B2 (en) | 2022-05-04 | 2025-08-05 | H. Lundbeck A/S | Crystalline forms of a MAGL inhibitor |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1593586A (enExample) | 1967-10-17 | 1970-06-01 | ||
| JPS6183073A (ja) | 1984-10-01 | 1986-04-26 | Oki Electric Ind Co Ltd | 印字装置の用紙送り方法 |
| WO1989011794A1 (fr) | 1988-06-07 | 1989-12-14 | Rikagaku Kenkyusho | Inhibiteur de la croissance de plantes |
| EP0619804B1 (en) | 1991-11-27 | 1996-05-22 | E.I. Du Pont De Nemours And Company | Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives |
| EP0736047B1 (en) | 1993-12-22 | 1998-03-04 | Shell Internationale Researchmaatschappij B.V. | Process for preparing carbamates |
| WO1997018196A1 (en) | 1995-11-15 | 1997-05-22 | Zeneca Limited | Herbicidal substituted pyrazole compounds |
| AU3440597A (en) | 1996-07-02 | 1998-01-21 | Novartis Ag | N-phenylimino heterocyclic derivatives and their use as herbicides |
| RU2167150C2 (ru) | 1998-03-25 | 2001-05-20 | Фокин Александр Васильевич | Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью |
| AU7856600A (en) | 1999-10-04 | 2001-05-10 | University Of Medicine And Dentistry Of New Jersey | Novel carbamates and ureas |
| EP1201298A1 (en) | 2000-10-24 | 2002-05-02 | Urea Casale S.A. | Carbamate condensation unit |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
| AU2003300702A1 (en) | 2003-12-31 | 2005-07-21 | Council Of Scientific And Industrial Research | Process for preparing carbamates |
| KR20070026382A (ko) | 2004-02-18 | 2007-03-08 | 아스트라제네카 아베 | 아세틸린성 피페라진 화합물 및 대사성 글루타메이트수용체 길항제로서 이들의 용도 |
| EP1831218A2 (en) | 2004-12-23 | 2007-09-12 | F.Hoffmann-La Roche Ag | Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| ME02929B (me) | 2004-12-30 | 2018-04-20 | Janssen Pharmaceutica Nv | DERIVATIVI FENILAMIDA 4-(BENZIL)-PIPERAZIN-1-KARBOKSILNE KISELINE l SLIĆNA JEDINJENJA KAO MODULATORI HIDROLAZE AMIDA MASNIH KISELINA (FAAH) ZA LEĆENJE ANKSIOZNOSTI, BOLA l OSTALIH STANJA |
| EP1948630A2 (en) * | 2005-11-05 | 2008-07-30 | AstraZeneca AB | Novel compounds |
| JP2009523729A (ja) | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎の治療方法 |
| EP2114941B1 (en) | 2006-12-22 | 2015-03-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
| CN101711154A (zh) | 2007-02-26 | 2010-05-19 | 科森生物科学公司 | 氨基甲酸酯化合物 |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| JP2011528368A (ja) | 2008-07-16 | 2011-11-17 | シェーリング コーポレイション | 二環式ヘテロ環誘導体およびｇｐｃｒモジュレーターとしてのその使用 |
| CA2743861A1 (en) | 2008-11-14 | 2010-05-20 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| WO2010111050A1 (en) | 2009-03-23 | 2010-09-30 | Banyu Pharmaceutical Co., Ltd. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
| RU2011147181A (ru) * | 2009-04-22 | 2013-05-27 | Янссен Фармацевтика Нв | Азетидинилдиамиды в качестве ингибиторов моноациглицерин-липазы |
| UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| ES2433235T3 (es) | 2009-11-03 | 2013-12-10 | Bayer Intellectual Property Gmbh | Fluorouretanos como aditivos en una formulación de fotopolímero |
| FR2960875B1 (fr) * | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| SMT202000198T1 (it) * | 2012-01-06 | 2020-07-08 | Scripps Research Inst | Composti di carbammato e metodi di produzione e di utilizzo degli stessi |
| HUE038403T2 (hu) | 2012-01-06 | 2018-10-29 | Agios Pharmaceuticals Inc | Terápiásan alkalmazható vegyületek és alkalmazási módszereik |
| MX2014011134A (es) | 2012-03-19 | 2014-12-10 | Abide Therapeutics Inc | Compuestos de carbamato y preparacion y uso de los mismos. |
| JP2014005245A (ja) * | 2012-06-26 | 2014-01-16 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン誘導体を含有する医薬組成物 |
| US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
| WO2015003002A1 (en) | 2013-07-03 | 2015-01-08 | Abide Therapeutics, Inc. | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| WO2016014975A2 (en) * | 2014-07-25 | 2016-01-28 | Northeastern University | Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof |
| US9771341B2 (en) | 2015-03-18 | 2017-09-26 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| US10899737B2 (en) * | 2016-09-19 | 2021-01-26 | Lundbeck La Jolla Research Center, Inc. | Piperazine carbamates and methods of making and using same |
| JOP20190105A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
-
2017
- 2017-06-16 JO JOP/2019/0106A patent/JOP20190106A1/ar unknown
- 2017-11-15 MX MX2019005776A patent/MX391117B/es unknown
- 2017-11-15 KR KR1020197016924A patent/KR20190077544A/ko not_active Abandoned
- 2017-11-15 EP EP17871753.4A patent/EP3541821A4/en not_active Withdrawn
- 2017-11-15 UA UAA201905620A patent/UA124542C2/uk unknown
- 2017-11-15 CR CR20190241A patent/CR20190241A/es unknown
- 2017-11-15 GE GEAP201715088A patent/GEP20237470B/en unknown
- 2017-11-15 MA MA046857A patent/MA46857A/fr unknown
- 2017-11-15 TN TNP/2019/000153A patent/TN2019000153A1/en unknown
- 2017-11-15 BR BR112019009994A patent/BR112019009994A2/pt not_active IP Right Cessation
- 2017-11-15 GE GEAP202215088A patent/GEAP202215088A/en unknown
- 2017-11-15 JP JP2019523587A patent/JP7042547B2/ja not_active Expired - Fee Related
- 2017-11-15 RU RU2019116512A patent/RU2754536C1/ru active
- 2017-11-15 US US15/814,322 patent/US10093635B2/en active Active
- 2017-11-15 IL IL266523A patent/IL266523B/en unknown
- 2017-11-15 AR ARP170103184A patent/AR110089A1/es not_active Application Discontinuation
- 2017-11-15 CA CA3043615A patent/CA3043615A1/en active Pending
- 2017-11-15 AU AU2017361251A patent/AU2017361251B2/en not_active Ceased
- 2017-11-15 WO PCT/US2017/061868 patent/WO2018093947A1/en not_active Ceased
- 2017-11-15 EA EA201991073A patent/EA038090B1/ru unknown
- 2017-11-15 PE PE2019001014A patent/PE20191144A1/es unknown
- 2017-11-15 CN CN201780083663.6A patent/CN110267963B/zh not_active Expired - Fee Related
- 2017-11-16 TW TW106139775A patent/TWI756299B/zh not_active IP Right Cessation
-
2019
- 2019-05-16 CO CONC2019/0005059A patent/CO2019005059A2/es unknown
- 2019-05-16 PH PH12019501097A patent/PH12019501097A1/en unknown
- 2019-05-16 NI NI201900051A patent/NI201900051A/es unknown
- 2019-05-16 DO DO2019000122A patent/DOP2019000122A/es unknown
- 2019-05-16 CL CL2019001339A patent/CL2019001339A1/es unknown
- 2019-05-16 EC ECSENADI201935077A patent/ECSP19035077A/es unknown
- 2019-05-17 ZA ZA201903100A patent/ZA201903100B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551934A1 (en) | Magl inhibitors | |
| PH12019501097A1 (en) | Magl inhibitors | |
| PH12019501102A1 (en) | Magl inhibitors | |
| MX2017011997A (es) | Carbamatos de piperacina y metodos de preparacion y uso. | |
| PH12019502646A1 (en) | Pyrazole magl inhibitors | |
| PH12019501079A1 (en) | Magl inhibitors | |
| GB2541571A (en) | Pharmaceutical compositions | |
| PH12020500371A1 (en) | Spirocycle compounds and methods of making and using same | |
| MX378273B (es) | Compuestos activos hacia bromodominios. | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| MX2019014042A (es) | Inhibidores pirazolicos de magl. | |
| MX383227B (es) | Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosomico. | |
| PH12020500372A1 (en) | Spirocycle compounds and methods of making and using same | |
| MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
| BR112017000730B8 (pt) | Derivados de pirrolidinona como inibidores de metap-2, e medicamentos | |
| NZ756915A (en) | Dual magl and faah inhibitors | |
| PH12017500602A1 (en) | Methods for treating ocular conditions | |
| MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
| EA201790156A1 (ru) | Азетидинилоксифенилпирролидиновые соединения | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| EA201891848A1 (ru) | Фармацевтическая композиция для применения в лечении фиброза |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status |
Owner name: I-MAB BIOPHARMA US LIMITED |